A novel steroidal antiandrogen targeting wild type and mutant androgen receptors

Andrieu, Thomas; Bertolini, Reto; Nichols, Sara E; Setoud, Raschid; Frey, Felix J; Baker, Michael E; Frey, Brigitte M (2011). A novel steroidal antiandrogen targeting wild type and mutant androgen receptors. Biochemical pharmacology, 82(11), pp. 1651-62. New York, N.Y.: Elsevier 10.1016/j.bcp.2011.08.020

Full text not available from this repository. (Request a copy)

Prostate cancer (PCa) progression is enhanced by androgen and treatment with antiandrogens represents an alternative to castration. While patients initially respond favorably to androgen ablation therapy, most experience a relapse of the disease within 1-2 years by expressing androgen receptor (AR) mutants. Such mutations, indeed, promote unfavorable agonistic behavior from classical antagonists. Here, we have synthesized and screened 37 novel compounds derived from dihydrotestosterone (DHT), cyanolutamide and hydroxyflutamide. These derivatives were tested for their potential antagonistic activity using a luciferase reporter gene assay and binding properties were determined for wild type (WT) and mutant ARs (T877A, W741C, W741L, H874Y). In the absence and presence of antiandrogens, androgen dependent cellular proliferation and prostate specific antigen (PSA) expression were assayed in the prostate cancer cell line LNCaP by crystal violet, real time PCR and by Western blots. Also, cellular proliferation and PSA expression were assayed in 22Rv1. A novel compound RB346, derived from DHT, was found to be an antagonist for all tested AR forms, preventing DHT induced proliferation and PSA expression in LNCaP and 22Rv1 cells. RB346 displayed no agonistic activity, in contrast to the non-steroidal antiandrogen bicalutamide (Casodex) with unfavorable agonistic activity for W741L-AR. Additionally, RB346 has a slightly higher binding affinity for WT-AR, T877A-AR and H874Y-AR than bicalutamide. Thus, RB346 is the first potent steroidal antiandrogen with efficacy for WT and various AR mutants.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension
UniBE Contributor:	Frey, Felix (B), Frey, Brigitte
ISSN:	0006-2952
Publisher:	Elsevier
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:17
Last Modified:	29 Mar 2023 23:32
Publisher DOI:	10.1016/j.bcp.2011.08.020
PubMed ID:	21907706
Web of Science ID:	000296931400013
URI:	https://boris.unibe.ch/id/eprint/5338 (FactScience: 210078)